Israeli Company Wins FDA Approval For Bone Cancer Treatment

Israeli med-tech company InSightec Image Guided Treatment has announced that it has been approved for US Food and Drug Administration (FDA) premarketing of its ExAblate targeted focused ultrasound treatment for the removal of bone tumors.

According to Globes online business magazine, the initial approval is for patients who cannot or will not undergo radiation therapy.

According to InSightec, 30% of bone cancer patients cannot undergo radiation treatment.

InSightec is controlled by Elbit Medical Technologies.